JP2015526709A - 生体外におけるがんの診断及び監視方法 - Google Patents

生体外におけるがんの診断及び監視方法 Download PDF

Info

Publication number
JP2015526709A
JP2015526709A JP2015519081A JP2015519081A JP2015526709A JP 2015526709 A JP2015526709 A JP 2015526709A JP 2015519081 A JP2015519081 A JP 2015519081A JP 2015519081 A JP2015519081 A JP 2015519081A JP 2015526709 A JP2015526709 A JP 2015526709A
Authority
JP
Japan
Prior art keywords
cells
treg
tumor
ratio
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015519081A
Other languages
English (en)
Japanese (ja)
Inventor
バルツンコバー、ジリナ
シュピーシュエク、ラデク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EXCOSO A. S.
Original Assignee
EXCOSO A. S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EXCOSO A. S. filed Critical EXCOSO A. S.
Publication of JP2015526709A publication Critical patent/JP2015526709A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/4915—Blood using flow cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514—CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70517—CD8
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ecology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
JP2015519081A 2012-07-02 2013-06-27 生体外におけるがんの診断及び監視方法 Pending JP2015526709A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20120174539 EP2682750A1 (en) 2012-07-02 2012-07-02 In vitro method for the diagnosis and surveillance of cancer
EP12174539.2 2012-07-02
US201261672941P 2012-07-18 2012-07-18
US61/672,941 2012-07-18
PCT/EP2013/063448 WO2014005909A1 (en) 2012-07-02 2013-06-27 In vitro method for the diagnosis and surveillance of cancer

Publications (1)

Publication Number Publication Date
JP2015526709A true JP2015526709A (ja) 2015-09-10

Family

ID=46397089

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015519081A Pending JP2015526709A (ja) 2012-07-02 2013-06-27 生体外におけるがんの診断及び監視方法

Country Status (18)

Country Link
US (1) US20150337384A1 (forum.php)
EP (2) EP2682750A1 (forum.php)
JP (1) JP2015526709A (forum.php)
KR (1) KR20150035521A (forum.php)
CN (1) CN104364656A (forum.php)
AU (1) AU2013286134A1 (forum.php)
BR (1) BR112014026661A2 (forum.php)
CA (1) CA2872668A1 (forum.php)
CL (1) CL2014002975A1 (forum.php)
EA (1) EA201500080A1 (forum.php)
HK (1) HK1202618A1 (forum.php)
IL (1) IL236197A0 (forum.php)
IN (1) IN2015DN00678A (forum.php)
MX (1) MX2014013079A (forum.php)
PH (1) PH12014502436A1 (forum.php)
SG (1) SG11201406581UA (forum.php)
WO (1) WO2014005909A1 (forum.php)
ZA (1) ZA201409298B (forum.php)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020521152A (ja) * 2017-05-19 2020-07-16 ロイヤル・メルボルン・インスティテュート・オブ・テクノロジーＲｏｙａｌ Ｍｅｌｂｏｕｒｎｅ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｔｅｃｈｎｏｌｏｇｙ シクロホスファミド療法に対する応答者の予測
JP2022500658A (ja) * 2018-09-20 2022-01-04 ヴェンタナ メディカル システムズ， インク． フローサイトメトリデータを分析するためのサイズに基づくゲーティング

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2514591A (en) * 2013-05-30 2014-12-03 Mologen Ag Predictive biomarker for cancer therapy
EP3111221B2 (en) 2014-02-24 2022-01-19 Ventana Medical Systems, Inc. Methods, kits, and systems for scoring the immune response to cancer by simultaneous detection of cd3, cd8, cd20 and foxp3.
US20150323547A1 (en) * 2014-03-14 2015-11-12 Brian J. Czerniecki Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration
US20160266125A1 (en) * 2015-03-12 2016-09-15 John Wayne Cancer Institute Methods of treating and predicting progression of cancer based on t cell subsets
CN108135945A (zh) * 2015-06-22 2018-06-08 哈佛大学校长及研究员协会 固有层调节性t细胞的诱导
JP6100867B1 (ja) * 2015-11-06 2017-03-22 振武 曽 免疫状態の分析のための検査方法
CN106932576A (zh) * 2017-03-22 2017-07-07 山东大学深圳研究院 一种人调节性t细胞的免疫抑制功能的检测方法
TWI793151B (zh) 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
CN108508196B (zh) * 2018-04-13 2020-10-27 何韶衡 一种检测人调节性t细胞亚型的试剂盒及检测方法
HRP20231295T1 (hr) 2018-07-10 2024-02-02 Novartis Ag Derivati 3-(5-hidroksi-1-oksoizoindolin-2-il)piperidin-2,6-diona i njihova upotreba u liječenju bolesti ovisnih o cinkovom prstu 2 (ikzf2) obitelji ikaros
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020521152A (ja) * 2017-05-19 2020-07-16 ロイヤル・メルボルン・インスティテュート・オブ・テクノロジーＲｏｙａｌ Ｍｅｌｂｏｕｒｎｅ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｔｅｃｈｎｏｌｏｇｙ シクロホスファミド療法に対する応答者の予測
US11573234B2 (en) 2017-05-19 2023-02-07 Royal Melbourne Institute Of Technology Predicting responders to cyclophosphamide therapy
JP7255896B2 (ja) 2017-05-19 2023-04-11 ロイヤル・メルボルン・インスティテュート・オブ・テクノロジー シクロホスファミド療法に対する応答者の予測
JP2022500658A (ja) * 2018-09-20 2022-01-04 ヴェンタナ メディカル システムズ， インク． フローサイトメトリデータを分析するためのサイズに基づくゲーティング
JP7259019B2 (ja) 2018-09-20 2023-04-17 ヴェンタナ メディカル システムズ， インク． フローサイトメトリデータを分析するためのサイズに基づくゲーティング
US12385922B2 (en) 2018-09-20 2025-08-12 Ventana Medical Systems, Inc. Size-based gating to analyze flow cytometry data

Also Published As

Publication number Publication date
CN104364656A (zh) 2015-02-18
WO2014005909A1 (en) 2014-01-09
ZA201409298B (en) 2015-12-23
EA201500080A1 (ru) 2015-06-30
PH12014502436A1 (en) 2015-01-12
CA2872668A1 (en) 2014-01-09
IN2015DN00678A (forum.php) 2015-06-26
BR112014026661A2 (pt) 2017-06-27
EP2682750A1 (en) 2014-01-08
US20150337384A1 (en) 2015-11-26
CL2014002975A1 (es) 2015-04-24
HK1202618A1 (en) 2015-10-02
EP2867677A1 (en) 2015-05-06
IL236197A0 (en) 2015-01-29
KR20150035521A (ko) 2015-04-06
SG11201406581UA (en) 2015-01-29
AU2013286134A1 (en) 2015-01-22
MX2014013079A (es) 2014-12-08

Similar Documents

Publication Publication Date Title
JP2015526709A (ja) 生体外におけるがんの診断及び監視方法
Kryczek et al. IL-17+ regulatory T cells in the microenvironments of chronic inflammation and cancer
Partlová et al. Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma
JP6664684B1 (ja) がん免疫療法の臨床効果を予測する免疫学的バイオマーカー
Costa et al. Tumor-associated macrophages and the profile of inflammatory cytokines in oral squamous cell carcinoma
Roufosse et al. Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome
Vujanovic et al. CD56dim CD16− natural killer cell profiling in melanoma patients receiving a cancer vaccine and interferon-α
Rezvani et al. Graft-versus-leukemia effects associated with detectable Wilms tumor-1–specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia
Mathew et al. The anergic state in sarcoidosis is associated with diminished dendritic cell function
Talpur et al. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma
Wheeler et al. Thymic CD8+ T cell production strongly influences tumor antigen recognition and age-dependent glioma mortality
Ghirelli et al. Breast cancer Cell–derived GM-CSF licenses regulatory Th2 induction by plasmacytoid predendritic cells in aggressive disease subtypes
Pawelec et al. MDSCs, ageing and inflammageing
EP2942629A1 (en) Predictive markers for successful cancer immunotherapy
Lattanzi et al. iNKT cell-neutrophil crosstalk promotes colorectal cancer pathogenesis
Wågsäter et al. Quantification of the chemokines CCL17 and CCL22 in human colorectal adenocarcinomas
Riabov et al. Immunostimulatory early phenotype of tumor-associated macrophages does not predict tumor growth outcome in an HLA-DR mouse model of prostate cancer
Lin et al. Increased percentage of B cells in patients with more advanced hepatocellular carcinoma
Wiegering et al. Lower TGFß serum levels and higher frequency of IFNγ‐producing T cells during early immune reconstitution in surviving children after allogeneic stem cell transplantation
US20240066061A1 (en) A cxcr3+ cell or cell preparation for use in cancer treatment
Jainarayanan et al. 173P Pseudotime dynamics in pancreatic ductal adenocarcinoma reveal different mechanisms of hindrance in immunity through bifurcation of regulatory and cytotoxic T-cell differentiation
Djordjevic Role of bacteria-reactive T lymphocytes in immune responses against human colorectal cancer
Mishinov et al. Cytotoxic activity of interferon alpha induced dendritic cells as a biomarker of glioblastoma
Rouanne Mechanisms of resistance to BCG immunotherapy in bladder cancer
Algazi et al. In Situ Transfection of Interleukin 12 Plasmid Enhances Anti-PD-1 Immune Response in Patients with Immunologically Quiescent Melanoma